全文获取类型
收费全文 | 159877篇 |
免费 | 10126篇 |
国内免费 | 1227篇 |
专业分类
耳鼻咽喉 | 2442篇 |
儿科学 | 2696篇 |
妇产科学 | 2631篇 |
基础医学 | 25236篇 |
口腔科学 | 3644篇 |
临床医学 | 15201篇 |
内科学 | 29201篇 |
皮肤病学 | 4796篇 |
神经病学 | 13474篇 |
特种医学 | 8659篇 |
外科学 | 20715篇 |
综合类 | 1008篇 |
现状与发展 | 4篇 |
一般理论 | 39篇 |
预防医学 | 9422篇 |
眼科学 | 4088篇 |
药学 | 14046篇 |
中国医学 | 1584篇 |
肿瘤学 | 12344篇 |
出版年
2023年 | 1077篇 |
2022年 | 3102篇 |
2021年 | 5054篇 |
2020年 | 2506篇 |
2019年 | 3565篇 |
2018年 | 4387篇 |
2017年 | 3524篇 |
2016年 | 4601篇 |
2015年 | 6287篇 |
2014年 | 7476篇 |
2013年 | 8864篇 |
2012年 | 13251篇 |
2011年 | 12674篇 |
2010年 | 7288篇 |
2009年 | 6281篇 |
2008年 | 9044篇 |
2007年 | 8788篇 |
2006年 | 7949篇 |
2005年 | 7430篇 |
2004年 | 6547篇 |
2003年 | 5755篇 |
2002年 | 5059篇 |
2001年 | 3948篇 |
2000年 | 3666篇 |
1999年 | 2886篇 |
1998年 | 1214篇 |
1997年 | 966篇 |
1996年 | 771篇 |
1995年 | 719篇 |
1994年 | 607篇 |
1993年 | 578篇 |
1992年 | 1333篇 |
1991年 | 1302篇 |
1990年 | 1157篇 |
1989年 | 1124篇 |
1988年 | 1034篇 |
1987年 | 1031篇 |
1986年 | 818篇 |
1985年 | 857篇 |
1984年 | 646篇 |
1983年 | 513篇 |
1982年 | 372篇 |
1981年 | 382篇 |
1980年 | 325篇 |
1979年 | 518篇 |
1978年 | 416篇 |
1977年 | 298篇 |
1976年 | 289篇 |
1974年 | 336篇 |
1973年 | 336篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
Chang Y Jung Hyo S Choi Jin S Ju Hyo S Park Tae G Kwon Yong C Bae Dong K Ahn 《The journal of pain》2006,7(10):747-756
The present study investigated the role of central metabotropic glutamate receptors (mGluRs) in interleukin-1beta (IL-1beta)-induced mechanical allodynia and mirror-image mechanical allodynia in the orofacial area. Experiments were carried out on male Sprague-Dawley rats weighing 230 to 280 g. After administration of 0.01, 0.1, 1, or 10 pg of IL-1beta into a subcutaneous area of the vibrissa pad, we examined the withdrawal behavioral responses produced by 10 successive trials of an air-puff ramp pressure applied ipsilaterally or contralaterally to the IL-1beta injection site. Subcutaneous injection of IL-1beta produced mechanical allodynia and mirror-image mechanical allodynia in the orofacial area. Intracisternal administration of CPCCOEt, a mGluR1 antagonist, or MPEP, a mGluR5 antagonist, reduced IL-1beta-induced mechanical allodynia and mirror-image mechanical allodynia. Intracisternal administration of APDC, a group II mGluR agonist, or L-AP4, a group III mGluR agonist, reduced both IL-1beta-induced mechanical allodynia and mirror-image mechanical allodynia. The antiallodynic effect, induced by APDC or L-AP4, was blocked by intracisternal pretreatment with LY341495, a group II mGluR antagonist, or CPPG, a group III mGluR antagonist. These results suggest that groups I, II, and III mGluRs differentially modulated IL-1beta-induced mechanical allodynia, as well as mirror-image mechanical allodynia, in the orofacial area. PERSPECTIVE: Central group I mGluR antagonists and groups II and III mGluR agonists modulate IL-1beta-induced mechanical allodynia and mirror-image mechanical allodynia in the orofacial area. Therefore, the central application of group I mGluR antagonists or groups II and III mGluR agonists might be of therapeutic value in treating pain disorder. 相似文献
42.
J H Newcorn J M Halperin J M Healey J D O'Brien D M Pascualvaca L E Wolf A Morganstein V Sharma J G Young 《Journal of the American Academy of Child and Adolescent Psychiatry》1989,28(5):734-738
To assess the relationship between the DSM-III criteria for attention deficit disorder with hyperactivity (ADDH) and the DSM-III-R criteria for attention-deficit hyperactivity disorder (ADHD), children from an inner city parochial school were evaluated using a 30-item teacher questionnaire consisting of the DMS-III and DSM-III-R criteria for these disorders, the revised Conners Parent and Teacher Questionnaires, and a continuous performance test. Diagnostic groups were established based on teacher ratings of the DSM items and evaluated in relation to the rating scale data and continuous performance test. While children who were identified by teachers as having ADDH almost always satisfied the criteria for ADHD, a new group of children who were hyperactive and impulsive but less clearly inattentive also met the criteria for ADHD. Implications of the change in diagnostic criteria are discussed. 相似文献
43.
44.
Taylor Moran-Gates Christopher Grady Young Shik Park Ross J Baldessarini Frank I Tarazi 《European neuropsychopharmacology》2007,17(6-7):448-455
The atypical antipsychotic risperidone is often prescribed to pediatric patients with neuropsychiatric disorders, though its effects on the developing brain remain unclear. Accordingly, we studied the effects of repeated treatment of risperidone on dopamine receptors in brain regions of juvenile rat. Levels of dopamine receptors (D(1), D(2), D(3), D(4)) in forebrain regions of juvenile rats were quantified after 3 weeks of treatment with three different doses of risperidone (0.3, 1.0 and 3.0 mg/kg) and compared findings to those in adult rats treated with risperidone (3.0 mg/kg/day) previously. Risperidone (at 1.0 and 3.0 mg/kg/day) increased levels of D(1) receptors in nucleus accumbens and caudate-putamen of juvenile, but not adult rats. Conversely, all three doses of risperidone dose-dependently increased D(2) labeling in medial prefrontal cortex and hippocampus, and D(4) receptor in nucleus accumbens, caudate-putamen and hippocampus of juvenile animals as well as in adults. Only the high dose of risperidone (3.0 mg/kg) increased D(2) receptors in caudate-putamen in both juvenile and adult brain. D(3) receptors were not altered by risperidone in any brain region at any dose or age. The findings indicate dose-dependent effects of risperidone on dopamine receptors in developing animals, and that juvenile animals are more sensitive than adults to the cerebral effects of risperidone. 相似文献
45.
46.
47.
48.
49.
Diseases like rotavirus afflict both upper- and lower-income countries, but most serious illnesses and deaths occur among the latter. It is a vital public health issue that vaccines for these types of global diseases can recover research and development (R&D) costs from high-priced markets quickly so that manufacturers can offer affordable prices to lower-income nations. Cost recovery depends on how high R&D costs are, and this study attempts to replace high, unverified estimates with lower, more verifiable estimates for two new vaccines, RotaTeq (Merck) and Rotarix (GlaxoSmithKline or GSK), based on detailed searches of public information and follow-up interviews with senior informants. We also offer a new perspective on “cost of capital” as a claim for recovery from public bodies. Our estimates suggest that companies can recover all fixed costs quickly from affluent markets and thus can offer these vaccines to lower-income countries at prices they can afford. Better vaccines are a shared project between companies and public health agencies; greater transparency and consistency in reporting of R&D costs is needed so that fair prices can be established. 相似文献
50.